Intravitreal Ganciclovir Treatment in Progressive Outer Retinal Necrosis

Pérez-Blázquez, Eugenio; Traspas, Rocío; Marín, I. Méndez; Montero, Marta

doi:10.1016/s0002-9394(14)70845-1

Cited by 38 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Responses to intravenous acyclovir or ganciclovir have been inconsistent and disappointing, with 49%-67% of involved eyes progressing to no light perception [91,226]. Several case reports have reported improved preservation of vision in patients treated with a combination of intravenous ganciclovir plus foscarnet, with or without intravitreal antivirals [227][228][229][230][231][232]. Cidofovir has also been used successfully in a small number of patients [233,234].…”

Section: Treatment Of Complicated Presentations Of Hzmentioning

confidence: 99%

Recommendations for the Management of Herpes Zoster

Dworkin

Johnson

Breuer

et al. 2007

Clinical Infectious Diseases

716

581

View full text Add to dashboard Cite

The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ.

show abstract

Section: Treatment Of Complicated Presentations Of Hzmentioning

confidence: 99%

Recommendations for the Management of Herpes Zoster

Dworkin

Johnson

Breuer

et al. 2007

Clinical Infectious Diseases

716

581

View full text Add to dashboard Cite

show abstract

“…Intravitreal foscarnet can be administered at a dose of 2.4 mg/0.1 ml, which requires no dilution from the commercially available intravenous solution, and may be administered immediately following diagnostic sampling of aqueous or vitreous fluid. High dose intravitreal injections of ganciclovir have also been used for the treatment of active herpetic retinal necrosis in both immunosuppressed59 60 and immunocompetent13 61 62 patients. The typical dose of 2 mg/0.1 ml intravitreal ganciclovir is given two or three times weekly.…”

Section: Medical Treatment Of Arnmentioning

confidence: 99%

Emerging concepts in the management of acute retinal necrosis

et al. 2012

View full text Add to dashboard Cite

Acute retinal necrosis (ARN), also known as Kirisawa-type uveitis, is an uncommon condition caused by infection of the retina by one of the herpes family of viruses, most typically varicella zoster virus or herpes simplex virus and less commonly cytomegalovirus. Clinical diagnosis can be challenging and is often aided by PCR-based analysis of ocular fluids. Treatment typically involves extended use of one or more antiviral agents. Long term retinal detachment risk is high. We review the literature on ARN and present an approach to the diagnosis and management of this serious condition.

show abstract

“…11,12 However, the use of intravitreal injections for the treatment of ARN has become increasingly common in the recent past, and several reports have been published describing the effectiveness of this local treatment. [13][14][15][16][17] In addition, recent reports have described successful treatment of ARN with either oral famciclovir or valacyclovir alone without precedent intravenous or intravitreal antiviral therapy. 18,19 The aims of this study were to determine visual acuity outcome based on the severity of retinitis and to assess the effect of treatment modality on visual acuity outcome of patients with ARN.…”

mentioning

confidence: 99%